N-Acetylcysteine for Hyperpigmentation: Thiol Mechanisms, the Oral Trial Failure and the Topical Evidence

N-acetylcysteine (NAC) occupies an uncomfortable position in pigment science. It is one of the most heavily prescribed antioxidants in clinical medicine — the standard antidote for acetaminophen overdose, a mucolytic in pulmonary care — and its thiol chemistry gives it two plausible routes into melanogenesis. Yet when the controlled trials are read side by side, NAC’s hyperpigmentation evidence splits sharply: the topical data look encouraging, the oral data are negative. This review examines both, and what the divergence means for anyone formulating a brightening product.

The Two Mechanisms Behind NAC

NAC is a thiol — a molecule carrying a sulfhydryl (−SH) group. That single functional group drives both of its proposed anti-melanogenic actions.

1. Cysteine donation and the pheomelanin switch. After absorption, NAC is deacetylated to L-cysteine, the rate-limiting substrate for glutathione (GSH) synthesis. Raising intracellular GSH changes the competitive balance inside the melanocyte: higher GSH availability favors pheomelanin (yellow-red) over eumelanin (dark brown-black), because the thiol competes for the reactive intermediates in the eumelanin branch of the pathway. In practical terms, the pigment that is produced is lighter, and tyrosinase activity is suppressed by the elevated thiol environment.

2. Copper chelation at tyrosinase. The sulfur of the thiol group has a high affinity for copper. Because tyrosinase is a copper-dependent metalloenzyme, NAC can complex with the copper ions in its active site and inhibit catalytic activity directly — a mechanism distinct from the glutathione route, and one that does not require conversion to cysteine first.

Both mechanisms are coherent in cell culture. The question is whether they translate to visible depigmentation in humans — and here the route of administration matters enormously.

Topical Evidence: Encouraging but Entangled

The foundational topical study is the double-blind, placebo-controlled, split-face trial by Njoo, Menke, Pavel and Westerhof. Twelve women with symmetrical facial melasma applied a cream containing 4.7% NAC plus 2% hydroquinone (HQ) to one side of the face and the cream base to the other, twice daily for four months, with a sunblock applied over both sides. Mild-to-strong bleaching was observed on the active side in 9 of 10 evaluable patients; the base-only side showed no significant change in those same patients. No side effects attributable to NAC were reported.

That result seeded what is still called the Westerhof formula. Its clinical life has not ended: a 2026 registered trial (ClinicalTrials.gov NCT07508098) is comparing a triple combination of 4.7% NAC, 2% HQ and 0.1% triamcinolone acetonide against 4% HQ alone over eight weeks, with the proportion of patients achieving a 60% reduction in the Melasma Area and Severity Index (MASI-60) as the primary endpoint. The fact that a NAC-based formula is still being tested against HQ monotherapy three decades later speaks to genuine, if modest, clinical interest.

The honest caveat is confounding. In every published topical NAC trial with positive results, NAC was co-formulated with hydroquinone. There is no well-powered trial isolating topical NAC’s own contribution, and no trial testing NAC alone against HQ. A reasonable reading is that NAC acts as a complementary thiol — lowering the HQ concentration needed, or blunting the oxidative and inflammatory load — rather than as a standalone bleaching agent.

Oral Evidence: A Clean Negative

The oral picture is far less forgiving. A 2024 randomized, parallel, double-blind, placebo-controlled trial (Alfredo et al., Anais Brasileiros de Dermatologia) enrolled 50 women with moderate-to-severe facial melasma (mMASI > 4) and randomized them to oral NAC 600 mg twice daily or matching placebo for eight weeks, with all participants using a tinted broad-spectrum SPF 60 sunscreen reapplied every three hours.

The results were flatly negative. Both groups reduced their mMASI by 12% (95% CI 8–19% for NAC versus 5–21% for placebo; p = 0.613). Secondary endpoints agreed: MELASQoL quality-of-life scores (p = 0.941) and colorimetry (p = 0.709) showed no separation, and blinded photographic global improvement (GAIS) did not reach significance (p = 0.317). NAC was well tolerated — a few cases of heartburn, epigastric discomfort and drowsiness — but it was not superior to placebo. This was the first trial to test oral NAC as monotherapy, and it failed.

The mechanistic explanation is bioavailability. Oral NAC is an efficient hepatic glutathione precursor, but it does not reliably raise glutathione inside melanocytes at concentrations sufficient to meaningfully suppress melanin synthesis. The oxidative-stress hypothesis of melasma may be correct — serum glutathione peroxidase correlates with disease severity — without oral NAC being the right tool to exploit it.

NAC in the Wider Thiol Family

Placing NAC alongside its thiol relatives clarifies the picture. A 2022 review of thiol compounds for skin lightening catalogues the evidence: oral glutathione combined with cystine outperformed either agent alone; cysteamine 5% cream has multiple randomized trials showing reductions in pigmented skin comparable or slightly inferior to hydroquinone, but with better tolerability. Against those, NAC is the least clinically validated of the group — positive only when co-formulated with HQ topically, and negative orally. Its sulfur chemistry is legitimate; its clinical dossier is thin.

Formulation Considerations

For a formulator, NAC’s practical problem is stability. The same thiol group that chelates copper and donates cysteine also oxidizes readily in aqueous systems, converting to cystine and disulfides with an attendant sulfur odor and loss of activity. Workable strategies include:

• Anhydrous or low-water vehicles, which limit oxidative degradation.
• pH control and chelation, keeping the formulation in a range that slows thiol oxidation while preserving the copper-binding capacity.
• Encapsulation — liposomal or cyclodextrin delivery — to shield the thiol and improve penetration.
• Antioxidant co-formulation (for example, with a compatible antioxidant network) to protect the active during shelf life.

Concentrations in the literature cluster around 4.7% in the classic HQ-combination formula and up to 10% in photodamage studies, where NAC cream reduced matrix metalloproteinase activity. Packaging in airless or opaque formats is standard practice for thiol-containing products.

Clinical Bottom Line

N-acetylcysteine is a credible antioxidant with two plausible anti-melanogenic mechanisms, and its topical combination data are genuinely positive — but they are inseparable from hydroquinone. Its one well-powered oral trial in melasma was a clean negative. The defensible position is to treat NAC as a supporting thiol: useful for lowering the oxidative and inflammatory burden of a brightening regimen, valuable for photoprotective MMP suppression, and best deployed alongside better-validated actives such as tranexamic acid, niacinamide and cysteamine rather than as a primary depigmenting agent. The engineering problem — keeping the thiol reduced and active through shelf life — is as important as the concentration chosen.

References

1. Njoo MD, Menke HE, Pavel S, Westerhof W. N-Acetylcysteine as a bleaching agent in the treatment of melasma. J Eur Acad Dermatol Venereol. 1997;9(1):86–87.
2. Alfredo MAC, Holanda IRM, Cassiano DP, Lima PB, Espósito ACC, Miot HA. Lack of efficacy of oral N-acetylcysteine in the treatment of facial melasma in women: a randomized, double-blind, placebo-controlled clinical trial. An Bras Dermatol. 2024. doi:10.1016/j.abd.2024.04.008.
3. Sonthalia S, Daulatabad D, Sarkar R. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol. 2018;84(6):652–658.
4. Metabolic Basis and Clinical Evidence for Skin Lightening Effects of Thiol Compounds. Antioxidants (Basel). 2022. PMC8944565.
5. Seçkin HY, Kalkan G, Baş Y, et al. Oxidative stress status in patients with melasma. Cutan Ocul Toxicol. 2014;33(3):212–217.
6. Comparison of Efficacy of Topical Westerhoff Formula Cream vs Topical 4% Hydroquinone for the Treatment of Melasma. ClinicalTrials.gov identifier NCT07508098.